Immunoglobulin-resistant delayed hemolytic transfusion reaction treated with rituximab in an adult sickle cell patient. by Delmonte L et al.
L E T T E R
Immunoglobulin-resistant delayed
hemolytic transfusion reaction treated with
rituximab in an adult sickle cell patient
Sickle cell disease (SCD) is a worldwide distributed hemo-
globinopathy and transfusion strategies are required for
treatment of acute and chronic SCD-related clinicalmani-
festations.1,2 The delayed hemolytic transfusion reaction
(DHTR) is a life-threatening transfusion complication of
SCD.3-6 The DHTR is defined by the acute decrease of
hemoglobin (Hb) levels with hemolysis and hemoglobin-
uria after 2 or 3 to 15 days after the blood transfusion. The
hemolytic phenotype of DHTR is associated with symp-
toms of severe sickle cell–related vasoocclusive crisis such
as pain.3-6 Although alloantibodies and autoantibodies
have been identified in few DHTR patients, the mecha-
nism(s) responsible for red blood cell (RBC) destruction in
DHTR is largely unknown.3-6 Recently intravenous immu-
noglobulin (IVIG) has been proposed for treatment of
DHTR in children with SCD,6 although previous case
reports described the use of the monoclonal chimeric
anti-CD20 antibody (rituximab) for treating or preventing
DHTR in children or in adult patients with SCD.3-5 A
26-year-old man with SCD (SS, HbS: 79%) was referred in
June 2012 to our department for severe vasoocclusive
crisis with bone pain and fever (Fig. 1). He was treated
with fluids, analgesics, and erythrocytapheresis using
antigen-matched RBCs.1 The patient was negative for
direct antiglobulin test (DAT). On Day 3 after erythrocyta-
pheresis Hb levels decreased (10.4-6.7 g/dL), the lactate
dehydrogenase (LDH) values increased (700-2200 U/L)
with hemoglobinuria and worsening of bone pain (Fig. 1).
The DAT was still negative and the diagnosis of DHTR was
made. The patient was treated with IVIG at the dosage of
0.5 g/kg/day for 5 days (Fig 1). Steroids were avoided,
since the patient was admitted to the hospital for severe
acute vasoocclusive crisis and steroids can worsen the
acute clinical manifestation related to SCD.We observed a
gradual amelioration of the patient’s pain, whereas Hb
levels were still low, associated with hemoglobinuria and
persistence of high LDH levels despite the increased
reticulocyte count, suggesting a DHTR resistant to immu-
noglobulin treatment (Fig. 1). On Day 11 after erythro-
cytapheresis and on Day 4 after the end of the
immunoglobulin treatment, the patient again experi-
enced severe pain with abdominal localization and
further reduction of Hb level. The abdominal ultrasonog-
raphy showed splenic sequestration. Since we hypoth-
esized a DHTR resistant to immunoglobulin treatment
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Fig 1. Clinical presentation of the immunoglobulin (Ig)-resistant DHTR episode in a adult patient with SCD. The arrows indicate:
erythrocytapheresis treatment (EEX) and the administration of rituximab (Rtx) followed by transfusion of RBCs. ( ) LDH (U/L);
( ) Hb (g/dL).
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and we needed to transfuse the patient before and/or
during splenectomy, we used rituximab (375 mg/m2)
before transfusion of RBCs.5 The serology for hepatitis B
was compatible with past infection. The patient under-
went a splenectomy. In the following days the Hb levels
rapidly increased, the LDH levels reduced, and the hemo-
globinuria disappeared with amelioration of the patient’s
clinical condition. TheHb levels were stable (11.8 g/dL) 15
and 40 days after rituximab. The DAT was still negative 30
days after the patient’s discharge. The patient was then
placed under hydroxyurea treatment to reduce the trans-
fusion requirement. Although rituximab treatment was
effective in DHTR, it must be pointed out that SCD
patients treated with rituximab should be closely followed
up due to the fact that rituximab can induce prolonged
immunosuppression, which might expose SCD to the risk
of severe infections. This case suggests that a portion of
SCD patients with DHTR might be resistant to immuno-
globulin treatment.6 Thus, in these patients rituximab
should be considered as a therapeutic option.
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